William McKee, MD
Pulmonary Disease · Dyersburg, TNNPI 1104810704
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,800 of the $53,798 with a category attached, or 90.7%. GSK accounts for 89.2% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2023 at $17,736 and has fallen 95.8% since, to $751 in 2025. Among pulmonary disease clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 301 payments — averaging $178.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$48K
- Viiv Healthcare Company$2K
- Novo Nordisk$1K
- AstraZeneca$622
- Boehringer Ingelheim$333
- Mylan Specialty L.p.$233
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$48,80091%
- Travel & lodging$2360%
- Food & beverage$4,7269%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 48 | $47,989 |
| Viiv Healthcare Company | 1 | $1,600 |
| Novo Nordisk | 81 | $1,277 |
| AstraZeneca | 37 | $622 |
| Boehringer Ingelheim | 17 | $333 |
| Mylan Specialty L.p. | 18 | $233 |
| Bayer | 14 | $223 |
| Amgen | 13 | $200 |
| Insmed, Inc. | 7 | $171 |
| Lilly USA, LLC | 11 | $155 |
| Verona Pharma, Inc. | 6 | $108 |
| Intuitive Surgical | 1 | $91 |
| Pfizer | 5 | $87 |
| Abbott | 4 | $78 |
| Baxter Healthcare | 4 | $78 |
| AbbVie | 5 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Exact Sciences | 3 | $55 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Kowa Pharmaceuticals America, Inc. | 2 | $41 |
| Novartis | 2 | $36 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Genentech USA, Inc. | 2 | $25 |
| Grifols USA, LLC | 2 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$26,700
- ANORO$3,704
- SYMBICORT$113
- FARXIGA$113
- BEVESPI AEROSPHERE$113
How this compares
$53,798 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 364 | $263,176 |
| OfevNintedanib Esylate | 11 | $141,950 |
| EliquisApixaban | 102 | $86,261 |
| RybelsusSemaglutide | 59 | $74,094 |
| JardianceEmpagliflozin | 76 | $59,135 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 106 | $56,125 |
| Breo ElliptaFluticasone/Vilanterol | 131 | $53,769 |
| FarxigaDapagliflozin Propanediol | 52 | $37,609 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $35,247 |
| XareltoRivaroxaban | 39 | $32,229 |
| OzempicSemaglutide | 28 | $28,495 |
| JanuviaSitagliptin Phosphate | 19 | $23,551 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $12,966 |
| InvokanaCanagliflozin | 14 | $12,400 |
| TrulicityDulaglutide | 13 | $12,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $47,989 | $384,609615 claims |
| Boehringer IngelheimOfev, Jardiance, Combivent Respimat, Tradjenta | $333 | $225,967124 claims |
| Novo NordiskRybelsus, Ozempic | $1,277 | $102,58987 claims |
| PfizerEliquis | $87 | $86,261102 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $622 | $85,837135 claims |
| MerckJanuvia | $13 | $23,55119 claims |
| Lilly USA, LLCTrulicity | $155 | $12,05313 claims |
| AbbVieSynthroid | $76 | $4,38366 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $41 | $3,74612 claims |
| Sanofi-aventis U.S. LLCLantus | $25 | $3,37336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Dyersburg
- Lisa LancasterNashville$519K
- Krishnendu BhadraChattanooga$494K
- Aaron MilstoneFranklin$482K
- Otis RickmanNashville$392K
- Michael CzarneckiChattanooga$348K
- Susan GarwoodNashville$343K
- Girendra HoskereBristol$285K
- Carlos BaleeiroChattanooga$265K
- Joao DeandradeNashville$245K
- John SwisherKnoxville$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.